Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1949 2
1957 1
1958 1
1959 2
1960 2
1961 1
1962 1
1964 1
1965 4
1966 5
1967 3
1968 3
1969 3
1970 6
1971 8
1972 5
1973 3
1974 7
1975 18
1976 13
1977 8
1978 22
1979 29
1980 18
1981 63
1982 40
1983 45
1984 43
1985 61
1986 52
1987 51
1988 48
1989 49
1990 45
1991 32
1992 58
1993 19
1994 30
1995 30
1996 21
1997 16
1998 27
1999 31
2000 27
2001 36
2002 28
2003 27
2004 17
2005 20
2006 27
2007 16
2008 12
2009 22
2010 21
2011 16
2012 21
2013 20
2014 15
2015 25
2016 14
2017 21
2018 11
2019 14
2020 20
2021 12
2022 14
2023 13
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

1,361 results

Results by year

Filters applied: . Clear all
Page 1
Anthralin.
[No authors listed] [No authors listed] 2023 Apr 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Apr 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 37094056 Free Books & Documents. Review.
Topical anthralin has not been studied during breastfeeding. Anthralin has suspected mutagenic properties, so it should only be used if the potential benefit to the mother justifies potential risk to the infant.[1] If anthralin is used, ensure that the infant …
Topical anthralin has not been studied during breastfeeding. Anthralin has suspected mutagenic properties, so it should only b …
Anthralin/dithranol in dermatology.
Sehgal VN, Verma P, Khurana A. Sehgal VN, et al. Int J Dermatol. 2014 Oct;53(10):e449-60. doi: 10.1111/j.1365-4632.2012.05611.x. Epub 2014 Sep 10. Int J Dermatol. 2014. PMID: 25208745 Review.
Anthralin (1,8-dihydroxy-9anthrone, dithranol) was first synthesized as a derivative of chrysarobin, prepared from the araroba tree in Brazil over a century ago. Drawbacks to the use of anthralin include irritation and discoloration of the skin. This property
Anthralin (1,8-dihydroxy-9anthrone, dithranol) was first synthesized as a derivative of chrysarobin, prepared from the araroba
[Dithranol].
Melhorn S. Melhorn S. Hautarzt. 2017 May;68(5):421-423. doi: 10.1007/s00105-017-3977-5. Hautarzt. 2017. PMID: 28401270 German. No abstract available.
Anthralin.
Shroot B. Shroot B. Dermatologica. 1986;173(6):261-3. doi: 10.1159/000249268. Dermatologica. 1986. PMID: 3817237 No abstract available.
Psoriasis in children: a guide to its diagnosis and management.
Leman J, Burden D. Leman J, et al. Paediatr Drugs. 2001;3(9):673-80. doi: 10.2165/00128072-200103090-00005. Paediatr Drugs. 2001. PMID: 11688598 Review.
Most patients respond to topical treatment with emollients, coal tar, anthralin (dithranol) or calcipotriol. Treatment is tailored according to patient age, extent and distibution of psoriasis. ...
Most patients respond to topical treatment with emollients, coal tar, anthralin (dithranol) or calcipotriol. Treatment is tail …
Syntheses of Anthracenones. 2. Preparation of 1,8-Dimethoxy- (Dimethylanthralin) and 4,5-Dihydroxy-9(10H)-anthracenone (Isoanthralin): A Revision.
Prinz H, Burgemeister T, Wiegrebe W, Müller K. Prinz H, et al. J Org Chem. 1996 Apr 19;61(8):2857-2860. doi: 10.1021/jo952036t. J Org Chem. 1996. PMID: 11667123
Furthermore, the reduction of 1,8-diacetoxyanthracenedione with SnCl(2) in HCl and acetic acid leads to 1,8-dihydroxy-9(10H)-anthracenone (anthralin) rather than 4,5-dihydroxy-9(10H)-anthracenone (isoanthralin), which was prepared …
Furthermore, the reduction of 1,8-diacetoxyanthracenedione with SnCl(2) in HCl and acetic acid leads to 1,8-dihydroxy- …
Dithranol.
Mahrle G. Mahrle G. Clin Dermatol. 1997 Sep-Oct;15(5):723-37. doi: 10.1016/s0738-081x(97)00019-9. Clin Dermatol. 1997. PMID: 9313971 Review. No abstract available.
PUVA or dithranol?
Whitefield M. Whitefield M. Br Med J. 1978 Jul 15;2(6131):206. doi: 10.1136/bmj.2.6131.206-a. Br Med J. 1978. PMID: 697982 Free PMC article. No abstract available.
Anthralin (dithranol) in vitro inhibits human monocytes to secrete IL-6, IL-8 and TNF-alpha, but not IL-1.
Mrowietz U, Jessat H, Schwarz A, Schwarz T. Mrowietz U, et al. Br J Dermatol. 1997 Apr;136(4):542-7. Br J Dermatol. 1997. PMID: 9155955
Anthralin is a most widely used compound for topical treatment of psoriasis. Whereas numerous studies have ascertained anthralin as a safe and effective drug its mode of action still remains unclear. ...
Anthralin is a most widely used compound for topical treatment of psoriasis. Whereas numerous studies have ascertained anthralin
Optimized dithranol-imiquimod-based transcutaneous immunization enables tumor rejection.
Hartmann AK, Bartneck J, Pielenhofer J, Meiser SL, Arnold-Schild D, Klein M, Stassen M, Schild H, Muth S, Probst HC, Langguth P, Grabbe S, Radsak MP. Hartmann AK, et al. Front Immunol. 2023 Sep 1;14:1238861. doi: 10.3389/fimmu.2023.1238861. eCollection 2023. Front Immunol. 2023. PMID: 37727790 Free PMC article.
Previously, we reported on the combined application of the TLR7 agonist imiquimod (IMQ) together with the anti-psoriatic drug dithranol as novel TCI platform DIVA (dithranol/IMQ based vaccination). ...RESULTS: Applying the adjuvants on separate skin sites, a reduced …
Previously, we reported on the combined application of the TLR7 agonist imiquimod (IMQ) together with the anti-psoriatic drug dithranol
1,361 results